Patents by Inventor Jordan J. N. Tang
Jordan J. N. Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7829669Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: GrantFiled: August 3, 2007Date of Patent: November 9, 2010Assignees: Oklahoma Medical Research Foundation, The Board of Trustees of the University of IllinoisInventors: Gerald Koelsch, Jordan J. N. Tang, Lin Hong, Arun K. Ghosh, Xinli Lin
-
Publication number: 20100267609Abstract: Compounds inhibit memapsin 2 ?-secretase activity and selectively inhibit memapsin 2 ?-secretase activity relative to memapsin 1 ?-secretase activity. The compounds are employed in methods to inhibit memapsin 2 ?-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a ?-secretase site of a ?-amyloid precursor protein and to decrease ?-amyloid protein in in vitro samples and in mammals. Proteins of memapsin 2 associated with compounds of the invention are crystallized.Type: ApplicationFiled: June 9, 2009Publication date: October 21, 2010Inventors: Arun K. GHOSH, Jordan J. N. Tang, Geoffrey Bilcer, Wanpin Chang, Lin Hong, Gerald E. Koelsch, Jeffrey A. Loy, Robert T. Turner, III, Thippeswamy Devasumadram
-
Patent number: 7678760Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: GrantFiled: June 14, 2007Date of Patent: March 16, 2010Assignees: The Board of Trustees of the University of Illinois, Oklahoma Medical Research FoundationInventors: Jordan J. N. Tang, Arun K. Ghosh
-
Patent number: 7659289Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.Type: GrantFiled: September 19, 2005Date of Patent: February 9, 2010Assignees: CoMentis, Inc., Oklahoma Medical Research Foundation, The Board of Trustees of the University of IllinoisInventors: Arun K. Ghosh, Hui Lei, Thippeswamy Devasamudram, Jordan J. N. Tang, Geoffrey M. Bilcer, Chunfeng Liu
-
Publication number: 20090214554Abstract: The present invention provides novel methods of reducing memapsin 2 ?-secretase activity in a subject, decreasing levels of ?-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of ?-amyloid plaques in the brain of a subject. The methods may include the step of administering an effective amount of truncated memapsin 2 protein, anti-truncated memapsin 2 antibody, and/or nucleic acid encoding a truncated memapsin 2 protein or anti-truncated memapsin 2 antibody. The present invention also provides related pharmaceutical compositions and uses thereof.Type: ApplicationFiled: September 17, 2008Publication date: August 27, 2009Applicant: Oklahoma Medical Research FoundationInventors: Wan Pin CHANG, Deborah Downs, Jordan J.N. Tang
-
Patent number: 7504420Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.Type: GrantFiled: August 9, 2006Date of Patent: March 17, 2009Assignees: CoMentis, Inc., The Board of Trustees of the University of Illinois, Oklahoma Medical Research Foundation, Purdue Research FoundationInventors: Arun K. Ghosh, Nagaswamy Kumaragurubaran, Chunfeng Liu, Thippeswamy Devasamudram, Hui Lei, Lisa M. Swanson, Sudha V. Ankala, Jordan J. N. Tang, Geoffrey M. Bilcer
-
Publication number: 20080207527Abstract: The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.Type: ApplicationFiled: September 19, 2005Publication date: August 28, 2008Applicants: CoMentis, Inc., The Board of Trutees of the University of Illinois, Oklahoma Medical Research FoundationInventors: Arun K. Ghosh, Hui Lei, Thippeswamy Devasamudram, Chunfeng Liu, Jordan J.N. Tang, Geoffrey Bilcer
-
Publication number: 20080125467Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.Type: ApplicationFiled: September 19, 2005Publication date: May 29, 2008Inventors: Arun K. Ghosh, Hui Lei, Thippeswamy Devasamudram, Jordan J. N. Tang, Geoffrey Bilcer, Chungfeng Liu
-
Publication number: 20080112946Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: August 3, 2007Publication date: May 15, 2008Inventors: Gerald Koelsch, Jordan J. N. Tang, Lin Hong, Arun K. Ghosh, Xinli Lin
-
Patent number: 7335632Abstract: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.Type: GrantFiled: September 17, 2004Date of Patent: February 26, 2008Assignee: CoMentis, Inc.Inventors: Arun K. Ghosh, Hui Lei, Thippeswamy Devasamudram, Chunfeng Liu, Jordan J. N. Tang, Geoffrey Bilcer
-
Patent number: 7244708Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined and were used to design substrate analogs of the natural -2 substrate that can inhibit the function of memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. The inhibition constant of OM99-2 is 1.6×10?9 M against recombinant pro-memapsin 2. Crystallography of memapsin 2 bound to this inhibitor was used to determine the three dimensional structure of the protein, and the importance of the various residues in binding. This information is useful for designing new inhibitors to memapsin 2, for diagnosing and treating and/or preventing Alzheimer's disease.Type: GrantFiled: April 8, 2004Date of Patent: July 17, 2007Assignees: Oklahoma Medical Research Foundation, The Board of Trustees of the University of IllinoisInventors: Jordan J. N. Tang, Arun K. Ghosh
-
Patent number: 6969731Abstract: HIV protease inhibitors are among the most powerful drugs in suppressing HIV in human patients. However, HIV developed resistance to all protease inhibitor drugs so far marketed or used in clinical trials. HIV generates resistance by mutating its protease. The strains of HIV containing mutant proteases less vulnerable to inhibitor drug are able to replicate better and maintain the infection. No effective principle exists for the design of resistance-proof HIV protease inhibitors (HIVPr). A new inhibitor has been developed based on a new concept for designing resistance invulnerable HIVPr inhibitors. In vitro data have shown that this inhibitor is effective against many known HIVPr mutants resistant to other HIVPr inhibitor drugs. The new concept is, therefore, generally applicable for the design of other resistance invulnerable HIVPr inhibitor drugs.Type: GrantFiled: February 18, 2000Date of Patent: November 29, 2005Assignees: The University of Illinois, Board of Trustees, The Oklahoma Medical Research FoundationInventors: Jordan J. N. Tang, Arun K. Ghosh
-
Publication number: 20040220079Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: February 6, 2004Publication date: November 4, 2004Applicants: Oklahoma Medical Research Foundation, The Board of Trustees of the University of IllinoisInventors: Gerald Koelsch, Jordan J.N. Tang, Lin Hong, Arun K. Ghosh
-
Publication number: 20040167075Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: April 8, 2004Publication date: August 26, 2004Applicants: Oklahoma Medical Research Foundation, The Board of Trustees of the University of IllinoisInventors: Jordan J. N. Tang, Arun K. Ghosh
-
Publication number: 20040121947Abstract: Compounds inhibit memapsin 2 &bgr;-secretase activity and selectively inhibit memapsin 2 &bgr;-secretase activity relative to memapsin 1 &bgr;-secretase activity. The compounds are employed in methods to inhibit memapsin 2 &bgr;-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a &bgr;-secretase site of a &bgr;amyloid precursor protein and to decrease &bgr;-amyloid protein in in vitro samples and in mammals. Proteins of memapsin 2 associated with compounds of the invention are crystallized.Type: ApplicationFiled: October 23, 2002Publication date: June 24, 2004Applicants: Oklahoma Medical Research Foundation, The Board of Trustees of the University of IllinoisInventors: Arun K. Ghosh, Jordan J. N. Tang, Geoffrey Bilcer, Wanpin Chang, Lin Hong, Gerald E. Koelsch, Jeffrey A. Loy, Robert T. Turner, Thippeswamy Devasumadram
-
Publication number: 20030092629Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed-, The substrate and subsite specificity of the catalytically active enzyme have been determined by a method which determines the initial hydrolysis rate of the substrates by using MALDI-TOF/MS. Alternatively, the subsite specificity of memapsin can be determined by probing a library of inhibitors with memapsin 2 and subsequently detecting the bound memapsin 2 with an antibody raised to memapsin 2 and an alkaline phosphatase conjugated secondary antibody. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2.Type: ApplicationFiled: December 28, 2001Publication date: May 15, 2003Applicant: Oklahoma Medical Research FoundationInventors: Jordan J. N. Tang, Gerald Koelsch, Arun K. Ghosh
-
Patent number: 6545127Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: GrantFiled: June 27, 2000Date of Patent: April 8, 2003Assignee: Oklahoma Medical Research FoundationInventors: Jordan J. N. Tang, Xinli Lin, Gerald Koelsch, Lin Hong
-
Publication number: 20020164760Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: February 28, 2001Publication date: November 7, 2002Applicant: Oklahoma Medical Research FoundationInventors: Xinli Lin, Gerald Koelsch, Jordan J.N. Tang
-
Publication number: 20020115600Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogues including isosteres at the sites of the critical amino acid residues were developed and the substrate analogues, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: April 30, 2001Publication date: August 22, 2002Applicant: Oklahoma Medical Research FoundationInventors: Gerald Koelsch, Jordan J.N. Tang, Lin Hong, Arun K. Ghosh
-
Publication number: 20020049303Abstract: Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs of the natural memapsin 2 substrate that can inhibit the function of memapsin 2. The substrate analogs are based on peptide sequences, shown to be related to the natural peptide substrates for memapsin 2. The substrate analogs contain at least one analog of an amide bond which is not capable of being cleaved by memapsin 2. Processes for the synthesis of two substrate analogs including isosteres at the sites of the critical amino acid residues were developed and the substrate analogs, OMR99-1 and OM99-2, were synthesized. OM99-2 is based on an octapeptide Glu-Val-Asn-Leu-Ala-Ala-Glu-Phe (SEQ ID NO:28) with the Leu-Ala peptide bond substituted by a transition-state isostere hydroxyethylene group (FIG. 1).Type: ApplicationFiled: February 28, 2001Publication date: April 25, 2002Inventors: Jordan J. N. Tang, Xinli Lin, Gerald Koelsch, Lin Hong